CRISIL reaffirms Sun Pharma''s FCCB rating
28 Dec 2005
Rs. 400 Million Commercial Paper Programme | P1+ (Reaffirmed) |
Rating agency CRISIL has reaffirmed its outstanding rating on Sun Pharmaceutical Industries Ltd.'s (Sun Pharma) commercial paper programme The agency's affirmation comes in the wake of Sun Pharma's acquisition of the assets of Able Laboratories Inc. (Able Labs), U.S., for a consideration of US $23.50 million (approximately Rs1.06 billion).
Sun Pharma is a fast-growing pharmaceutical company with a leading market position in the high-value cardiovascular and neuro-psychiatry segments. Able Labs has manufacturing facilities for generic pharmaceutical products in tablet, capsule, liquid and other dosage forms, including controlled release.
In May 2005, Able Labs suspended manufacturing and distribution of its entire product line and recalled all its products, due to non-conformance with U.S. Food and Drug Administration (USFDA) standards. The company is presently not generating any revenues, and is referred under Chapter 11 of the United States Bankruptcy Code. For the year ended December 31, 2004, Able Labs had reported a net profit of US $14 million on net sales of US $103 million.
Sun Pharma now plans to revalidate and resubmit some of Able Labs' products with the USFDA. According to the company, these products will have the potential to help it strengthen its U.S. operations, as and when approved by the federal agency. For the company, the acquisition is in line with its strategy of expanding its presence in the U.S. generics market and focusing on difficult-to-manufacture generics. The acquisition is funded out of Sun Pharma's available cash and marketable securities of over Rs18 bn.
According to CRISIL, the rating continues to reflect Sun Pharma's dominant position in the fast-growing therapeutic segments such as cardiovascular, diabetes, and gynaecology in the domestic market, as well as its growing presence in the international generics markets. It also reflects on the company's strong profitability. The company has reported operating profits of 38 per cent, and net profit margins of over 30 per cent, in the last three years.
Sun Pharma's rating strengths, according to CRISIL, are offset to an extent by the company's high gearing of 1.98 times as at March 31, 2005 (up from 0.27 times as at March 31, 2003), resulting from its large US $350 million foreign currency convertible bonds (FCCB) issue in November 2004. The company also remains exposed to growing competition in the global generics markets, and increasing exposure to the legal and regulatory risks therein, the agency said.
For the year ended March 31, 2005, Sun Pharma reported a profit after tax of Rs4 billion (Rs.3.31 billion in the previous year) on the net sales of Rs11.4 billion (Rs9.5 billion). For the half year ended September 30, 2005, Sun Pharma reported a net profit of Rs2.87 billion (Rs1.95 billion in the previous corresponding period) on net sales of Rs8.2 billion (Rs5.9 billion).
Featured articles
Lighter than air, yet very, very powerful
By Kiron Kasbekar | 03 Jan 2024
In March 2013 Chinese scientists pulled off a remarkable feat. They created the world’s lightest aerogel. Tipping the scales at a mere 0.16 milligrams per cubic centimeter – that’s a sixth of the weight of air!
COP28 explained: A closer look at COP28's climate change solutions
By Aniket Gupta | 27 Dec 2023
The 28th United Nations Climate Change Conference, also known as COP28, took place from 30th November 2023, to 13th December 2023, at Expo City in Dubai, United Arab Emirates.
What is a Ponzi scheme?
By Aniket Gupta | 06 Dec 2023
Ponzi schemes have long captivated the public imagination, drawing unsuspecting investors into a web of illusion and deception.
The Rise and Rise of HDFC Bank
03 Jul 2023
HDFC, which surged ahead of global majors like HSBC Holdings Plc and Citigroup Inc and left Indian peers like State Bank of India and ICICI Bank in market capitalisation, now ranks fourth largest among the world’s most valuable banks, after JPMorgan Chase & Co, Industrial and Commercial Bank of China Ltd and Bank of America Corp
India’s Millet Revolution To Enrich Global Food Basket
02 Apr 2023
Millets, a healthier and cheaper substitute to wheat and rice, are indigenous to many parts of the world, especially in the semiarid tropics of Asia and Africa, and offers a big scope for expanding production and consumption in the foodgrain deficient African continent
Market predator Hindenburg preys on Adani stock
06 Mar 2023
Almost a month after the damning report of short-seller Hindenburg Research on the Adani Group that claimed that the seven stocks within the group were about 85 per cent overvalued, one of the group's stocks, Adani Total Gas, closed at Rs835 on the BSE, down nearly 79 per cent from its 24 January level, almost close to reaching that valuation